Table 1.

Clinicopathologic characteristics of PD-L1 and B7x expression in patients with lung cancer

A. PD-L1
Discovery cohort (n = 195)Validation cohort (n = 197)
ParameterPD-L1 negativePD-L1 positivePParameterPD-L1 negativePD-L1 positiveP
Age, years67.769.90.20Age, years65.269.10.15
Gender0.65Gender0.99
 Female (n = 116)86 (74%)30 (26%) Female (n = 108)74 (69%)34 (31%)
 Male (n = 74)57 (77%)17 (23%) Male (n = 73)50 (68%)23 (32%)
Race0.19Race0.57
 Asian (n = 8)6 (75%)2 (25%) Asian (n = 0)
 AA (n = 15)10 (67%)5 (33%) AA (n = 3)3 (100%)0 (0%)
 Hispanic (n = 16)12 (75%)4 (25%) Hispanic (n = 10)6 (60%)4 (40%)
 White (n = 142)111 (78%)31 (22%) White (n = 97)61 (63%)36 (37%)
Histology0.08Histology0.17
 Adeno (n = 158)124 (78%)34 (22%) Adeno (n = 149)109 (73%)40 (27%)
 Squam (n = 8)5 (63%)3 (37%) Squam (n = 23)13 (57%)10 (43%)
 Large (n = 16)9 (56%)7 (44%) Large (n = 2)2 (100%)0 (0%)
Stage0.003Stage0.006
 I (n = 145)117 (81%)28 (19%) I (n = 119)89 (75%)30 (25%)
 II (n = 21)12 (49%)9 (21%) II (n = 27)19 (70%)8 (30%)
 III (n = 13)6 (46%)7 (54%) III (n = 24)10 (42%)14 (58%)
Lymph node involvement0.04Lymph node involvement0.04
 Neg (n = 144)112 (78%)32 (22%) Neg (n = 124)89 (72%)35 (28%)
 Pos (n = 27)16 (59%)11 (41%) Pos (n = 37)20 (54%)17 (46%)
Mutation status0.07Mutation status0.94
 EGFR (n = 19)18 (95%)1 (5%) EGFR (n = 27)19 (70%)8 (30%)
 KRAS (n = 20)16 (80%)4 (20%) KRAS (n = 48)33 (69%)15 (31%)
 WT/WT (n = 34)23 (68%)11 (32%) WT/WT (n = 57)38 (67%)19 (33%)
TIL score0.14TIL score0.26
 Absent (n = 10)8 (80%)2 (20%) Absent (n = 3)2 (67%)1 (33%)
 Low (n = 122)96 (79%)26 (21%) Low (n = 117)83 (71%)34 (29%)
 High (n = 54)35 (65%)19 (35%) High (n = 57)34 (60%)23 (40%)
B. B7x
Discovery cohort (n = 195)Validation cohort (n = 197)
ParameterB7x negativeB7x positivePParameterB7x negativeB7x positiveP
Age, years69.067.90.50Age, years68.266.10.43
Gender0.63Gender0.99
 Female (n = 112)36 (32%)76 (68%) Female (n = 103)36 (35%)67 (65%)
 Male (n = 73)21 (29%)52 (71%) Male (n = 70)19 (27%)51 (73%)
Race0.03Race0.85
 Asian (n = 7)1 (14%)6 (86%) Asian (n = 0)
 AA (n = 14)5 (36%)9 (64%) AA (n = 3)1 (33%)2 (67%)
 Hispanic (n = 16)8 (50%)8 (50%) Hispanic (n = 10)5 (50%)5 (50%)
 White (n = 139)37 (27%)102 (73%) White (n = 96)35 (36%)61 (64%)
Histology0.001Histology0.22
 Adeno (n = 153)37 (24%)116 (76%) Adeno (n = 138)42 (30%)96 (70%)
 Squam (n = 8)7 (87%)1 (13%) Squam (n = 24)11 (46%)13 (54%)
 Large (n = 16)8 (50%)8 (50%) Large (n = 2)1 (50%)1 (50%)
Stage0.71Stage0.08
 I (n = 141)42 (30%)99 (70%) I (n = 113)42 (37%)71 (63%)
 II (n = 21)8 (38%)13 (62%) II (n = 27)4 (15%)23 (85%)
 III (n = 13)4 (31%)9 (69%) III (n = 21)7 (33%)14 (67%)
Lymph node (N per TNM staging)0.94Lymph node (N per TNM staging)0.09
 N0 (n = 140)43 (31%)97 (69%) N0 (n = 122)41 (34%)81 (66%)
 N1 (n = 16)4 (25%)12 (75%) N1 (n = 19)2 (11%)17 (89%)
 N2 (n = 10)3 (30%)7 (70%) N2 (n = 15)6 (40%)9 (60%)
Mutation status0.13Mutation status0.13
 EGFR (n = 17)2 (12%)15 (88%) EGFR (n = 25)7 (28%)18 (72%)
 KRAS (n = 20)8 (40%)12 (60%) KRAS (n = 46)11 (24%)35 (76%)
 WT/WT (n = 34)12 (35%)22 (65%) WT/WT (n = 52)22 (42%)30 (58%)
TIL score0.15TIL score0.44
 Absent (n = 10)5 (50%)5 (50%) Absent (n = 3)0 (0%)3 (100%)
 Low (n = 122)35 (29%)87 (71%) Low (n = 115)38 (33%)77 (67%)
 High (n = 54)17 (32%)36 (68%) High (n = 58)17 (29%)41 (71%)
  • Abbreviation: AA, African American.